| ID | 10365 |
| Vaccine Name | TV-003/005 |
| Disease Name | Dengue fever |
| Disease Classification | Hemorrhagic |
| Virus Name | Dengue virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Live-attenuated |
| Vaccine Status | Phase 3 |
| Manufacturer | Merck & Co. Inc. |
| Year of Manufacturing | NA |
| Manufacturing Country | Brazil |
| Age | 2 - 59 years |
| Dosage | NA |
| Administration Route | Subcutaneous |
| Adjuvant | NA |
| Target Strain | Dengue virus serotypes (1, 2, 3 and 4) |
| Description | Mammalian cell vero culture |
| Approving Organisation | NA |
| Collaborating Organisation | National Institute of Allergy and Infectious Diseases |
| Other Countries | NA |
| Trade Name | TetraVax-DV |
| PMID | 30684747 |
| Clinical Trial ID | NCT02406729 |
| Reference Link | https://www.sciencedirect.com/science/article/pii/S1201971219300402 |
| Additional Links | https://clinicaltrials.gov/ct2/show/NCT02406729
|